Human Papillomavirus (HPV) Associated Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Human Papillomavirus (HPV) Associated Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2022, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.

Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 28, 14, 3, 43, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 2 molecules, respectively.

Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Human Papillomavirus (HPV) Associated Cancer – Overview
Human Papillomavirus (HPV) Associated Cancer – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Human Papillomavirus (HPV) Associated Cancer – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Papillomavirus (HPV) Associated Cancer – Companies Involved in Therapeutics Development
Abivax SA
Anteris Technologies Ltd
Apimeds Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Auro Vaccines LLC
Avalia Immunotherapies Ltd
Avidea Technologies Inc
Beijing Kangle Guardian Biotechnology Co Ltd
Beijing Kangleweishi Biotechnology Co Ltd
BioMed Valley Discoveries Inc
Biond Biologics Ltd
BioNTech SE
Blue Sky Immunotherapies GmbH
Bristol-Myers Squibb Co
Cellid Co Ltd
Chain Biotechnology Ltd
Chengdu Institute of Biological Products Co Ltd
Corvus Pharmaceuticals Inc
Cue Biopharma Inc
Cullinan Oncology Inc
Elicio Therapeutics Inc
eTheRNA Immunotherapies NV
EyeGene Inc
Genexine Inc
Gilead Sciences Inc
GSK plc
HaloVax
Hookipa Pharma Inc
iBio Inc
ImmunityBio Inc
Immunomic Therapeutics Inc
IMV Inc
Innovene
Inovio Pharmaceuticals Inc
Inthera Bioscience AG
ISA Pharmaceuticals BV
KinoPharma Inc
Kovina Therapeutics Inc
Merck & Co Inc
Merck KGaA
Myrio Therapeutics Pty Ltd
NexImmune Inc
Nykode Therapeutics ASA
OncoNano Medicine Inc
Onconova Therapeutics Inc
Oxford Vacmedix UK Ltd
Papivax LLC
Pathovax LLC
Pattern Pharma Inc
PDS Biotechnology Corp
Posvax Co Ltd
Precigen Inc
Privo Technologies Inc
Rafjik Inc
Repertoire Immune Medicines Inc
Rottapharm Biotech Srl
Rubius Therapeutics Inc
Shandong Boan Biotechnology Co Ltd
Shanghai Bovax Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shantha Biotechnics Pvt Ltd
Shuttle Pharmaceuticals Inc
Sirnaomics Ltd
Stemirna Therapeutics Ltd
Symvivo Inc
TCR Cure Biopharma Technology Co Ltd
Tessa Therapeutics Ltd
Theravectys SA
Toragen Inc
Touchlight Genetics Ltd
Transcenta Holding Ltd
Transgene SA
Turnstone Biologics Inc
UbiVac LLC
Vaccitech Plc
Vault Pharma Inc
Vectorite Biomedical Inc
ViciniVax BV
Vir Biotechnology Inc
Virion Therapeutics LLC
Virometix AG
Vittail Ltd
VLP The Vaccines Company SL
Voltron Therapeutics Inc
West Lake Biomedical Technology (Hangzhou) Co Ltd
Xiamen Innovax Biotech Co Ltd
Zhejiang Borui Biopharmaceutical Co Ltd
Human Papillomavirus (HPV) Associated Cancer – Drug Profiles
A-002 – Drug Profile
ABX-196 – Drug Profile
Alpha beta T cells – Drug Profile
aminolevulinic acid hydrochloride – Drug Profile
AMV-002 – Drug Profile
Antibodies to Inhibit E6 for HPV Associated Cancer – Drug Profile
Antibodies to Inhibit E7 for HPV Associated Cancer – Drug Profile
AVA-1156 – Drug Profile
avelumab – Drug Profile
AVT-01 – Drug Profile
Bi-specific Monoclonal Antibodies to Target CD3 and HPV16 E7 for Human Papilloma Virus (HPV) Associated Cancer – Drug Profile
bintrafusp alfa – Drug Profile
BION-301 – Drug Profile
BNT-113 – Drug Profile
BR-102 – Drug Profile
BVAC-C – Drug Profile
Cellular Immunotherapy for HPV Associated Cervical Cancer – Drug Profile
Cellular Immunotherapy for HPV Associated Cervical Cancer and Epithelial Ovarian Cancer – Drug Profile
Cellular Immunotherapy to Target HPV16 for Cervical Cancer – Drug Profile
CerviVax – Drug Profile
ciforadenant – Drug Profile
CNV-NT – Drug Profile
CUE-101 – Drug Profile
DPXE-7 – Drug Profile
Drug for Human Papillomavirus (HPV) Associated Cancer – Drug Profile
durvalumab – Drug Profile
EG-HPV – Drug Profile
EI-201 – Drug Profile
ETBX-041 – Drug Profile
feladilimab – Drug Profile
FIT-039 – Drug Profile
Fusion Protein to Target CD40 for HPV Associated Cervical, Head And Neck Cancer – Drug Profile
Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia – Drug Profile
Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer – Drug Profile
Gene Therapy to Target HPV E6 and E7 Proteins for Oncology – Drug Profile
Gene Therapy to Target HPV-16 E7 Protein for HPV-16 Associated Cancers – Drug Profile
GX-188E – Drug Profile
HB-201 – Drug Profile
HB-202 – Drug Profile
HPV vaccine – Drug Profile
human papillomavirus (15-valent) vaccine – Drug Profile
human papillomavirus (9 valent) vaccine – Drug Profile
human papillomavirus (heptavalent) vaccine – Drug Profile
human papillomavirus (virus like particle) vaccine – Drug Profile
human papillomavirus [Serotype 16] vaccine – Drug Profile
human papillomavirus [serotypes 16, 18, 58] (trivalent) vaccine – Drug Profile
human papillomavirus [serotypes 16, 31, 51] (trivalent) vaccine – Drug Profile
human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine – Drug Profile
human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58,59 and 68] (11-valent) vaccine – Drug Profile
human papillomavirus vaccine – Drug Profile
INO-3106 – Drug Profile
INTH-454 – Drug Profile
ISA-101 – Drug Profile
ISA-201 – Drug Profile
ITI-2000 – Drug Profile
Jade – Drug Profile
LY-01019 – Drug Profile
M-9241 – Drug Profile
MEDI-0457 – Drug Profile
Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer – Drug Profile
NEXI-001 – Drug Profile
NSC-721689 – Drug Profile
onalespib – Drug Profile
Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19) – Drug Profile
Oncolytic Virus to Target E6 and E7 for Human Papillomavirus (HPV) Associated Solid Tumors – Drug Profile
ONM-500 – Drug Profile
OVM-100 – Drug Profile
P2PAR-100 – Drug Profile
PANHPVAX – Drug Profile
PDS-0101 – Drug Profile
fvpembrolizumab – Drug Profile
PRGN-2009 – Drug Profile
PRV-121 – Drug Profile
PV-001 – Drug Profile
PVX-01 – Drug Profile
RFK-01 – Drug Profile
rigosertib sodium – Drug Profile
RPTR-168 – Drug Profile
RTX-321 – Drug Profile
sdCMV-002 – Drug Profile
SIM-325 – Drug Profile
Small Molecules to Inhibit E6AP for Human Papillomavirus (HPV) Associated Cancers and Prostate Cancer – Drug Profile
SP-259 – Drug Profile
STP-909 – Drug Profile
Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer – Drug Profile
TA-CIN – Drug Profile
TGNS-11 – Drug Profile
tipapkinogene sovacivec – Drug Profile
Tricurin – Drug Profile
TST-005 – Drug Profile
TT-12 – Drug Profile
Vaccine for HIV and HPV Associated Cancer – Drug Profile
Vaccine for HPV Associated Cancer – Drug Profile
Vaccine for HPV Associated Cervical Cancer – Drug Profile
Vaccine for HPV Associated Non-Melanoma Skin Cancer – Drug Profile
Vaccine for Human Papillomavirus (HPV) Associated Cancer – Drug Profile
Vaccine for Infectious Diseases and Oncology – Drug Profile
Vaccine to Target E6 and E7 for Human Papillomavirus (HPV) Associated Cancer – Drug Profile
Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia – Drug Profile
Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia And HPV Associated Head And Neck Squamous Cell Carcinoma – Drug Profile
VB-1016 – Drug Profile
VMT-2 – Drug Profile
VPI-241 – Drug Profile
VRON-0100 – Drug Profile
VRON-0101 – Drug Profile
VTP-200 – Drug Profile
Vvax-001 – Drug Profile
WTX-222 – Drug Profile
Human Papillomavirus (HPV) Associated Cancer – Dormant Projects
Human Papillomavirus (HPV) Associated Cancer – Discontinued Products
Human Papillomavirus (HPV) Associated Cancer – Product Development Milestones
Featured News & Press Releases
Jun 07, 2022: PDS Biotechnology to host conference call following poster presentations of PDS0101 data at 2022 ASCO Annual Meeting
May 26, 2022: PDS Biotech announces presentation of data from NCI-Led Triple combination Phase 2 clinical trial in advanced, refractory HPV-positive cancers at ASCO 2022
Mar 15, 2022: PDS Biotech announces achievement of an enrollment objective in National Cancer Institute-Led phase 2 clinical trial of PDS0101-based combination in advanced HPV-associated cancers
Feb 24, 2022: PDS Biotech announces preliminary safety data on PDS0101 in combination with KEYTRUDA (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium
Feb 15, 2022: PDS Biotech announces clinical trial with Mayo Clinic to study PDS0101 in early stage pre-metastatic- HPV-associated head and neck cancer
Feb 02, 2022: PDS Biotech announces preliminary efficacy achievement in VERSATILE-002 phase 2 trial of PDS0101 in combination with KEYTRUDA (pembrolizumab) in advanced head and neck cancer
Jan 10, 2022: PDS Biotech granted patent for its novel HPV16 immunotherapy
Jan 07, 2022: PDS Biotechnology updated its corporate presentation
Dec 06, 2021: Cue Biopharma to present at JMP Securities Hematology and Oncology Summit
Dec 06, 2021: PDS Biotech provides recruitment update for National Cancer Institute-Led phase 2 clinical trial of PDS0101-based combination
Sep 21, 2021: Cue Biopharma granted U.S. patents on lead clinical program novel drug product candidate CUE-101
Sep 20, 2021: PDS Biotech achieves safety requirement milestone for the first 12 patients in the VERSATILE-002 phase 2 combination trial of PDS0101-KEYTRUDA in advanced head and neck cancer
Sep 13, 2021: Merck to present on Bintrafusp Alfa at WCLC and ESMO 2021
Sep 09, 2021: PDS Biotech completes enrollment of lead-in safety cohort in VERSATILE-002 phase 2 combination trial of PDS0101-KEYTRUDA in recurrent or metastatic head and neck cancer
Jul 28, 2021: PDS Biotechnology to present recent phase 2 human clinical data and on-going oncology programs at Investor Conferences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
Table 6: Number of Products under Development by Universities/Institutes, 2022
Table 7: Products under Development by Companies, 2022
Table 8: Products under Development by Companies, 2022 (Contd..1)
Table 9: Products under Development by Companies, 2022 (Contd..2)
Table 10: Products under Development by Companies, 2022 (Contd..3)
Table 11: Products under Development by Companies, 2022 (Contd..4)
Table 12: Products under Development by Companies, 2022 (Contd..5)
Table 13: Products under Development by Universities/Institutes, 2022
Table 14: Number of Products by Stage and Target, 2022
Table 15: Number of Products by Stage and Target, 2022 (Contd..1)
Table 16: Number of Products by Stage and Mechanism of Action, 2022
Table 17: Number of Products by Stage and Route of Administration, 2022
Table 18: Number of Products by Stage and Molecule Type, 2022
Table 19: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Abivax SA, 2022
Table 20: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Anteris Technologies Ltd, 2022
Table 21: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Apimeds Inc, 2022
Table 22: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Astex Pharmaceuticals Inc, 2022
Table 23: Human Papillomavirus (HPV) Associated Cancer – Pipeline by AstraZeneca Plc, 2022
Table 24: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Auro Vaccines LLC, 2022
Table 25: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Avalia Immunotherapies Ltd, 2022
Table 26: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Avidea Technologies Inc, 2022
Table 27: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2022
Table 28: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Beijing Kangleweishi Biotechnology Co Ltd, 2022
Table 29: Human Papillomavirus (HPV) Associated Cancer – Pipeline by BioMed Valley Discoveries Inc, 2022
Table 30: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Biond Biologics Ltd, 2022
Table 31: Human Papillomavirus (HPV) Associated Cancer – Pipeline by BioNTech SE, 2022
Table 32: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Blue Sky Immunotherapies GmbH, 2022
Table 33: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Bristol-Myers Squibb Co, 2022
Table 34: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Cellid Co Ltd, 2022
Table 35: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Chain Biotechnology Ltd, 2022
Table 36: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Chengdu Institute of Biological Products Co Ltd, 2022
Table 37: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Corvus Pharmaceuticals Inc, 2022
Table 38: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Cue Biopharma Inc, 2022
Table 39: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Cullinan Oncology Inc, 2022
Table 40: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Elicio Therapeutics Inc, 2022
Table 41: Human Papillomavirus (HPV) Associated Cancer – Pipeline by eTheRNA Immunotherapies NV, 2022
Table 42: Human Papillomavirus (HPV) Associated Cancer – Pipeline by EyeGene Inc, 2022
Table 43: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Genexine Inc, 2022
Table 44: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Gilead Sciences Inc, 2022
Table 45: Human Papillomavirus (HPV) Associated Cancer – Pipeline by GSK plc, 2022
Table 46: Human Papillomavirus (HPV) Associated Cancer – Pipeline by HaloVax, 2022
Table 47: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Hookipa Pharma Inc, 2022
Table 48: Human Papillomavirus (HPV) Associated Cancer – Pipeline by iBio Inc, 2022
Table 49: Human Papillomavirus (HPV) Associated Cancer – Pipeline by ImmunityBio Inc, 2022
Table 50: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Immunomic Therapeutics Inc, 2022
Table 51: Human Papillomavirus (HPV) Associated Cancer – Pipeline by IMV Inc, 2022
Table 52: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Innovene, 2022
Table 53: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Inovio Pharmaceuticals Inc, 2022
Table 54: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Inthera Bioscience AG, 2022
Table 55: Human Papillomavirus (HPV) Associated Cancer – Pipeline by ISA Pharmaceuticals BV, 2022
Table 56: Human Papillomavirus (HPV) Associated Cancer – Pipeline by KinoPharma Inc, 2022
Table 57: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Kovina Therapeutics Inc, 2022
Table 58: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Merck & Co Inc, 2022
Table 59: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Merck KGaA, 2022
Table 60: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Myrio Therapeutics Pty Ltd, 2022
Table 61: Human Papillomavirus (HPV) Associated Cancer – Pipeline by NexImmune Inc, 2022
Table 62: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Nykode Therapeutics ASA, 2022
Table 63: Human Papillomavirus (HPV) Associated Cancer – Pipeline by OncoNano Medicine Inc, 2022
Table 64: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Onconova Therapeutics Inc, 2022
Table 65: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Oxford Vacmedix UK Ltd, 2022
Table 66: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Papivax LLC, 2022
Table 67: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Pathovax LLC, 2022
Table 68: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Pattern Pharma Inc, 2022
Table 69: Human Papillomavirus (HPV) Associated Cancer – Pipeline by PDS Biotechnology Corp, 2022
Table 70: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Posvax Co Ltd, 2022
Table 71: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Precigen Inc, 2022
Table 72: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Privo Technologies Inc, 2022
Table 73: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Rafjik Inc, 2022
Table 74: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Repertoire Immune Medicines Inc, 2022
Table 75: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Rottapharm Biotech Srl, 2022
Table 76: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Rubius Therapeutics Inc, 2022
Table 77: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Shandong Boan Biotechnology Co Ltd, 2022
Table 78: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Shanghai Bovax Biotechnology Co Ltd, 2022
Table 79: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022
Table 80: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Shantha Biotechnics Pvt Ltd, 2022
Table 81: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Shuttle Pharmaceuticals Inc, 2022
Table 82: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Sirnaomics Ltd, 2022
Table 83: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Stemirna Therapeutics Ltd, 2022
Table 84: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Symvivo Inc, 2022
Table 85: Human Papillomavirus (HPV) Associated Cancer – Pipeline by TCR Cure Biopharma Technology Co Ltd, 2022
Table 86: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Tessa Therapeutics Ltd, 2022
Table 87: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Theravectys SA, 2022
Table 88: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Toragen Inc, 2022
Table 89: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Touchlight Genetics Ltd, 2022
Table 90: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Transcenta Holding Ltd, 2022
Table 91: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Transgene SA, 2022
Table 92: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Turnstone Biologics Inc, 2022
Table 93: Human Papillomavirus (HPV) Associated Cancer – Pipeline by UbiVac LLC, 2022
Table 94: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Vaccitech Plc, 2022
Table 95: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Vault Pharma Inc, 2022
Table 96: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Vectorite Biomedical Inc, 2022
Table 97: Human Papillomavirus (HPV) Associated Cancer – Pipeline by ViciniVax BV, 2022
Table 98: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Vir Biotechnology Inc, 2022
Table 99: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Virion Therapeutics LLC, 2022
Table 100: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Virometix AG, 2022
Table 101: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Vittail Ltd, 2022
Table 102: Human Papillomavirus (HPV) Associated Cancer – Pipeline by VLP The Vaccines Company SL, 2022
Table 103: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Voltron Therapeutics Inc, 2022
Table 104: Human Papillomavirus (HPV) Associated Cancer – Pipeline by West Lake Biomedical Technology (Hangzhou) Co Ltd, 2022
Table 105: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Xiamen Innovax Biotech Co Ltd, 2022
Table 106: Human Papillomavirus (HPV) Associated Cancer – Pipeline by Zhejiang Borui Biopharmaceutical Co Ltd, 2022
Table 107: Human Papillomavirus (HPV) Associated Cancer – Dormant Projects, 2022
Table 108: Human Papillomavirus (HPV) Associated Cancer – Dormant Projects, 2022 (Contd..1)
Table 109: Human Papillomavirus (HPV) Associated Cancer – Dormant Projects, 2022 (Contd..2)
Table 110: Human Papillomavirus (HPV) Associated Cancer – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 10: Number of Products by Top 10 Molecule Types, 2022
Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings